In spite of some clinical trial reversals, recent studies of non-selective MMP inhibitors and anti-oxidants suggest that MMP-2 remains a compelling pharmacologic target for the treatment of cardiovascular disease [41], [42]. The gene discussed is MMP2; the disease is cardiovascular disorder.